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Vasiliki Matzaraki1 , Vinod Kumar1, Cisca Wijmenga1,2* and Alexandra Zhernakova1Abstract
In the past 50 years, variants in the major
histocompatibility complex (MHC) locus, also
known as the human leukocyte antigen (HLA),
have been reported as major risk factors for
complex diseases. Recent advances, including
large genetic screens, imputation, and analyses
of non-additive and epistatic effects, have contributed
to a better understanding of the shared and specific
roles of MHC variants in different diseases. We review
these advances and discuss the relationships between
MHC variants involved in autoimmune and infectious
diseases. Further work in this area will help to
distinguish between alternative hypotheses for
the role of pathogens in autoimmune disease
development.responses underlying disease onset and pathogenesis.Introduction
The major histocompatibility complex (MHC) locus,
also known as the human leukocyte antigen (HLA)
locus, spans around 4 Mbp on the short arm of chromo-
some 6 (6p21.3; Box 1). Molecules encoded by this
region are involved in antigen presentation, inflamma-
tion regulation, the complement system, and the innate
and adaptive immune responses, indicating the MHC’s
importance in immune-mediated, autoimmune, and
infectious diseases [1]. Over the past 50 years, polymor-
phisms in the MHC locus have been shown to influence
many critical biological traits and individuals’ suscepti-
bility to complex, autoimmune, and infectious diseases
(Boxes 2 and 3). In addition to autoimmune and inflam-
matory diseases, the MHC has recently been found to
play a role in some neurological disorders [2–6], impli-
cating autoimmune components in these diseases.* Correspondence: c.wijmenga@umcg.nl
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high levels of linkage disequilibrium (LD) compared to
the rest of the genome, which means there are technical
challenges in identifying MHC single nucleotide poly-
morphisms (SNPs), alleles, and amino acids. However,
the recent availability of dense genotyping platforms,
such as the custom-made Illumina Infinium SNP chip
(Immunochip) [7], and of MHC reference panels has
helped to fine-map the locus, improving our under-
standing of its disease associations and our ability to
identify functional variants.
In this review, we discuss recent advances in mapping
susceptibility variants in the MHC, using autoimmune
and infectious diseases as examples (Boxes 2 and 3). We
also discuss the relationships between the MHC variants
involved in both autoimmune and infectious diseases
and offer insights into the MHC-associated immune
Finally, we discuss future directions for studying genetic
variation in the MHC and how learning about the vari-
ation at this locus will aid understanding of disease
pathogenesis.Advances in mapping susceptibility variants in
the MHC locus
Several computational and empirical challenges compli-
cate the mapping of MHC susceptibility variants. One
fundamental challenge is that the MHC has many
sequence and structural variations [8], which differ
between populations and complicate haplotype infer-
ence. Another is that high and extensive LD in the locus
makes it difficult to identify causal and independent loci
Non-additive allelic effects in the MHC, and epistatic
effects between the MHC and other loci, can also com-
plicate inference of the underlying haplotype structure
and disease susceptibility variants.
In recent years, large volumes of sequencing data have
made it possible to impute MHC variation on a wide
scale, thereby improving our understanding of variability
at this locus and of the haplotype structures and
Box 1. The major histocompatibility complex locus
The major histocompatibility complex (MHC) was discovered in the
mouse in 1936 [128]. It covers 0.13% of the human genome [1] and
shows a high degree of polymorphism and extensive patterns of
linkage disequilibrium (LD), which differ among populations. The
large number of MHC alleles means each individual has a nearly
unique set of peptide-presenting allotypic MHC molecules, and each
MHC allotype confers the ability to bind different peptides. The
MHC genes are classified into five subregions from the telomeric to
the centromeric end: the extended class I, class I, class III, class II, and
the extended class II regions [1]. The extended MHC region contains
more than 400 annotated genes and pseudogenes that extend be-
yond the boundaries defining the MHC.
The class I region includes the three classic human leukocyte
antigen (HLA) gene loci: HLA-A, HLA-B, and HLA-C; three
non-classic HLA-E, HLA-F, and HLA-G gene loci, which show
limited polymorphism compared to the classic class I loci; and
other related non-coding genes and pseudogenes [1]. The main
function of HLA class I molecules, which are expressed in all
nucleated cells, is to present non-self antigens derived from
intracellular sources, such as viruses, to CD8+ T cells (cytotoxic
T cells), which then kill the antigen-presenting cells (APCs) [129].
CD8+ T cells interact with the cognate peptide-MHC I complexes
via their T-cell receptor (TCR) and co-receptor molecule CD8.
The class II region includes the classic gene loci HLA-DP,
HLA-DQ, and HLA-DR and also the non-classic HLA-DO and
HLA-DM loci [1]. The classic genes are expressed on the surface
of professional APCs, which take up antigens derived from
extracellular sources [130], such as bacteria or food, and present
them to CD4+ T helper cells. This leads to the secretion of
various small proteins, including cytokines, which regulate
other immune cells such as macrophages or B cells. In turn,
macrophages can destroy ingested microbes, and activated
B cells can secrete antibodies. CD4+ T cells interact with the
cognate peptide-MHC II complexes via their TCR and the
co-receptor molecule CD4. Non-classic molecules are exposed
in internal membranes in lysosomes, which help load antigenic
peptides on to classic MHC class II molecules.
The class III region contains genes involved in inflammation,
for example, complement cascades (C2, C4, CFB), and in
cytokine production (TNF, LTA, LTB), as well as many other
genes of non-immune or unknown function that may not be
involved in inflammation [1].
Overall, classic MHC I and II molecules present peptides for
T-cell surveillance and are, therefore, critical for priming the
cellular adaptive immune responses.
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of accurate reference panels and a large number of geno-
typed individuals has allowed the identification of inde-
pendent variants and improved our understanding of
their contribution to disease heritability and pathways
underlying disease biology [9, 10].
Advances in laboratory-based mapping of MHC variation
Increased throughput, accuracy, and read length in next-
generation sequencing (NGS) technologies, as well as
the development of user-friendly bioinformatics tools,
have enabled higher resolution MHC typing [11]. For in-
stance, whole-genome sequencing (WGS) was success-
fully used to type HLA-A alleles at full resolution in
1070 healthy Japanese individuals [12] and to fully evalu-
ate HLA-E variability in West African populations [13].
However, the main problem with MHC sequencing
using current technologies is the relatively short read
lengths, which limit the amount of allelic data that can
be generated at a high resolution. Long-range PCR
amplification approaches, such as the use of PacBio
systems for single molecule real-time sequencing, sig-
nificantly increase read-length and the resolution for
typing MHC alleles [14]. In a comparison of MHC
typing in an Indian population using sequence-
specific primers, NGS (Roche/454) and single mol-
ecule sequencing (PacBio RS II) platforms, higher
resolution typing was achieved for MHC class I (HLA-A,
HLA-B, and HLA-C ) and class II genes (HLA-DRB1 and
HLA-DQB1) using the PacBio platform, with a median
read length of 2780 nucleotides [15].
High-density SNP panels, such as the Immunochip
platform [7], which has been widely implemented in
immunogenetics studies, are a cheaper, faster, and easier
alternative to genotyping than direct MHC typing and
NGS methods. The Immunochip contains a dense panel
of SNPs from the MHC locus, which enables missing
classic MHC variants to be inferred in silico, where the
imputation is based on the haplotype structure present
in large reference panels (Fig. 1). This fine-mapping
approach has been used for several autoimmune and
inflammatory diseases (Table 1) and for a few infectious
diseases (Additional file 1), thereby allowing comprehen-
sive interrogation of the MHC. Moreover, population-
specific reference panels made by deep sequencing and
used to impute genotypes allow identification of very
rare variants and novel single-nucleotide variants in the
human genome. This is illustrated by a recent study in
which the authors first built a Han Chinese MHC-
specific database by deep sequencing the region in 9946
patients with psoriasis and 10,689 healthy controls, and
then used this reference panel to impute genotype data
to fine-map psoriasis-associated variants [16]. Notably,
functional variants in non-coding regions can be
Box 2. Clinical characteristics and prevalence of
autoimmune diseases in Europeans
Rheumatoid arthritis
Chronic inflammation of synovial joints, with a prevalence of
0.5–1%. In some individuals, rheumatoid arthritis can damage
a wide variety of body systems, including the skin, eyes, lungs,
heart, and blood vessels.
Celiac disease
Chronic inflammation of the intestine triggered by gluten
peptides in the diet and leading to flattening of the mucosa.
Prevalence is 0.5–2%.
Psoriasis
An inflammatory skin condition characterized by rapid growth
and skin cell reproduction. The disease trigger is unknown.
The prevalence is 0.5–1% worldwide, but it is higher (2%) in
Europeans.
Ankylosing spondylitis
A chronic, degenerative, and inflammatory form of arthritis,
primarily affecting the spine and sacroiliac joints, and
eventually leading to spinal fusion. This makes the spine less
flexible and can result in a hunchback posture. It has a
prevalence of 0.025%.
Systemic lupus erythematosus
Chronic inflammation that can affect any part of the body,
although it often attacks the heart, joints, skin, lungs, blood
vessels, liver, kidneys, and nervous system. It has a prevalence
of 0.04–0.12%.
Type 1 diabetes
Characterized by the destruction of pancreatic beta-cells, leading to
insufficient release of insulin from the pancreas. It has a prevalence
of 0.2–0.3%.
Multiple sclerosis
Characterized by autoimmune attack on the central nervous system,
leading to demyelination of neurons, and potentially debilitating
physical and mental symptoms. It has a prevalence of 0.02%.
Graves’ disease
An autoimmune thyroid disorder leading to the
overproduction of thyroid hormones (hyperthyroidism).
Graves’ disease occurs in about 0.5% of males and 3%
of females [131]. It is the most common cause of hyperthyroidism
in the USA, affecting about 1 in 200 people (0.5%) according
to the National Institutes of Health (https://ghr.nlm.nih.gov/
condition/graves-disease#statistics).
Inflammatory bowel disease
A group of intestinal disorders involving chronic inflammation
of the digestive tract. The two most common types of
inflammatory bowel disease are Crohn’s disease (CD), which is
characterized by inflammation of any part of the digestive tract,
and ulcerative colitis (UC), in which the inflammation is mostly
localized in the large intestine. In Europe, CD has a prevalence
varying from 0.00015 to 0.2%, whereas the prevalence of UC
varies from 0.0024 to 0.3% [132].
Dermatomyositis
A rare idiopathic myopathy characterized by inflammation,
primarily of the muscles and skin. It may also affect the joints,
esophagus, lungs, and heart. The disease incidence ranges from
1.2 to 17 new cases per 1,000,000 inhabitants, with a prevalence
between 0.005 and 0.011% [133].
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individuals [12]. These variants would be impossible to
discover using SNP microarrays or low coverage sequen-
cing on the same sample size (Fig. 1, Table 1).
MHC associations revealed by genome-wide associ-
ation studies (GWAS) can often not be fine-mapped to a
single allele at a single locus; rather they comprise
independent effects from multiple loci (see “Role of
MHC variants in human diseases”). The presence of
these multiple, independent effects highlights the hetero-
geneous nature within and between diseases, which may
lead to varying immunological responses. Fine-mapping
has also shown that autoimmune diseases share MHC
alleles and hence molecular pathways, which are likely
to represent targets for shared therapies. For instance,
the major associations within MHC class II across auto-
immune diseases imply that modulating T-cell receptor
(TCR) activation by using peptide-bearing MHC mole-
cules on antigen-presenting cells (APCs) could be thera-
peutically useful [17]. Shared MHC genetic factors have
also been observed between autoimmune and infectious
diseases, suggesting that human genetic architecture has
evolved in response to natural selection as determined
by various infectious pathogens [18].
Advances in computational approaches for mapping MHC
variation
Long-range LD between loci and SNP markers across
the MHC offers an alternative approach to interrogate
functional MHC variation through imputation. The de-
velopment of different imputation tools using
population-specific reference panels has enhanced the
interpretation of genotype data derived from genome-
wide platforms. MHC imputation is done using refer-
ence panels containing both genetic information and
classic HLA serotyping, thus allowing identification of
MHC allelic and amino acid variants. It is advantageous
to impute allele and amino acid variants in the MHC
because background sequence diversity causes the
binary SNP concept to fail, technically speaking, while
Box 3. Infectious diseases and infection-related GWAS phenotypes
HIV infection
Infection by the lentiviral human immunodeficiency virus (HIV; a subgroup of retrovirus) is a global public health issue. According to
the World Health Organization (WHO), 36.7 million people were living with HIV at the end of 2015 (http://www.who.int/). The virus
attacks human immune cells. Over time, HIV infection develops into acquired immunodeficiency syndrome (AIDS), a condition
characterized in humans by progressive loss of immune function and leading to life-threatening opportunistic infections and cancers.
Dengue shock syndrome
Dengue shock syndrome is the most dangerous and severe complication of infection with the dengue virus. It is characterized by
increased vascular permeability, together with myocardial dysfunction and dehydration. Dengue virus is a single, positive-stranded
RNA virus of the Flaviviridae family; it is mainly transmitted by mosquitos. Dengue is found in tropical and sub-tropical climates, mostly
in urban and semi-urban regions. The WHO estimates that about half of the world’s population is now at risk.
Hepatitis B virus infection
Hepatitis B virus (HBV) is a double-stranded DNA virus belonging to the Heoadnaviridae family. The virus can cause both acute and
chronic infections. Chronic infection with HBV leads to serious liver disease, often progressing to liver cirrhosis and hepatocellular
carcinoma [134]. The WHO estimates that about 240 million people live with chronic HBV infection worldwide, with the highest
prevalence seen in Africa and Asia.
Hepatitis C virus infection
Hepatitis C virus (HCV) is a single-stranded RNA virus of the Flaviviridae family. It has the same target as HBV—the liver—and can cause
both acute and chronic infections. The WHO estimates that 130–150 million people worldwide have chronic infection; many of these
will go on to develop liver cirrhosis or liver cancer. The prevalence of HCV infections is highest in Africa and Central and East Asia.
Human papillomavirus virus infection
Human papillomavirus virus (HPV) covers a highly diverse group of DNA papillomaviruses that are common worldwide. They can infect
either mucosal or cutaneous epithelia but, in most cases, can be cleared by the human immune system. If infection persists, certain
high-risk mucosal types (e.g., HPV16 and HPV18) can lead to cervical cancer and other anogenital and oropharyngeal cancers.
Leprosy
Leprosy is a chronic infectious disease caused by Mycobacterium leprae; it mainly affects the skin, peripheral nerves, mucosa of the
upper respiratory tract, and eyes. It is curable using multidrug therapy, which the WHO has made available free of charge to patients
worldwide since 1995. The WHO reports on leprosy in 121 countries and territories, but not in Europe, and gave a prevalence of 175,554
cases at the end of 2014. Thus, leprosy remains a serious public health problem, especially in developing countries. Leprosy is classified
into five distinct clinical subtypes. At one end of the spectrum, tuberculoid leprosy (TT) is characterized by fewer lesions and resistance
to mycobacteria proliferation, caused by a robust Th1 antigen-specific cellular response. In contrast, at the other end of the spectrum,
lepromatous leprosy (LL) is characterized by numerous lesions and proliferation of mycobacteria because of a weak or absent cellular
immune response and a dominant Th2 response. Between TT and LL, there is a range of intermediate forms and manifestations [135].
Tuberculosis
Tuberculosis is caused by Mycobacterium tuberculosis; it most often affects the lungs but can affect other parts of the body. It is one of
the top infectious killers worldwide, with over 95% of cases and deaths occurring in developing countries. Sub-Saharan Africa has the
highest disease prevalence. Pulmonary tuberculosis is the only transmissible form of the disease and the most common form seen in all
ages (WHO, Global Tuberculosis Report 2016; http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1). In 2015,
the WHO estimated 10.4 million new (incident) tuberculosis cases worldwide.
Leishmaniasis
Leishmaniasis is caused by the protozoan Leishmania parasites, which are transmitted to humans by infected female sandfly bites.
The disease has three forms: visceral (also known as kala-azar, the most serious form of the disease), cutaneous (the most common),
and mucocutaneous. It is classified as a neglected tropical disease, and the WHO estimates that there are 900,000 to 1.3 million
new cases and 20,000 to 30,000 deaths annually. Visceral leishmaniasis is endemic in the Indian subcontinent and in East Africa,
while cutaneous leishmaniasis is most common in the Americas, the Mediterranean basin, the Middle East, and Central Asia. Cases
of mucocutaneous leishmaniasis occur in South America (Bolivia, Peru, and Brazil; WHO Fact Sheet, updated September 2016;
(http://www.who.int/mediacentre/factsheets/fs375/en/).
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Fig. 1 Major histocompatibility complex imputation. A reference
cohort of subjects for whom both genetic information and classic
human leukocyte antigen (HLA) typing is available can be used
to infer the missing (untyped) genotypes and amino acids in a
discovery cohort. This allows imputed variants to be tested for their
associations with a disease of interest. The figure shows imputation
points to classic alleles associated with celiac disease risk in the
MHC region on chromosome 6. Y tyrosine, S serine, Q glutamine,
T threonine, R arginine, E glutamic acid
Matzaraki et al. Genome Biology  (2017) 18:76 Page 5 of 21many SNPs have more than two alleles and various
amino acids can be contained in the same position.
For instance, six possible amino acid variants at pos-
ition 11 in the HLA-DRB1 gene show the strongest
association to rheumatoid arthritis (RA) [19]. Two of
these (valine and leucine) confer susceptibility to RA,
whereas the other four (asparagine, proline, glycine
and serine) are protective.
Several tools allowing imputation of classic HLA
alleles at four-digit resolution are now available for MHC
imputation analysis; the most common are SNP2HLA
[20], HLA*IMP:01 [21], and an improved HLA*IMP:02
[22]. HLA*IMP:02 outperforms HLA*IMP:01 on hetero-
geneous European populations and it increases the power
and accuracy in cross-European GWAS [22]. Missing
data are also better tolerated in HLA*IMP:02, while
SNP genotyping platforms must be selected in
HLA*IMP:01 [21, 22]. SNP2HLA not only imputes
classic alleles but also amino acids by using two
European reference panels, one based on data from
HapMap-CEPH (90 individuals), and the other on the
Type 1 Diabetes Genetics Consortium (T1DGC) study
[20]. Another tool, HLA-VBSeq, allows imputation of
MHC alleles at full resolution from whole-genome se-
quence data [23]. HLA-VBSeq does not require prior
knowledge of MHC allele frequencies and can there-
fore be used for samples from genetically diverse pop-
ulations [23]. It has successfully typed HLA-A alleles
at full resolution in a Japanese population and identi-
fied rare causal variants implicated in complex human
diseases [12].
One commonly used European reference panel for im-
putation is the T1DGC panel, which covers SNP geno-
typing and classic HLA serotyping information for 5225
unrelated individuals [20]. Similar population-specific
reference panels have been developed for non-Europeanstudies to investigate the risk of psoriasis in Chinese
populations [16] and of Graves’ disease and RA in Japa-
nese populations. The panels have also been used to im-
pute MHC alleles and amino acids for East Asian and
Korean populations [24–26].
Using a single reference genome for regions like the
MHC, which has substantial sequence and structural di-
versity, results in poor characterization. To counteract
this, an algorithm was developed to infer much of the
variation in the MHC; it allows genome inference from
high-throughput sequencing data using known variation
represented in a population reference graph (PRG) [27].
Specifically, the PRG constructed for the MHC com-
bined eight assembled haplotypes, the sequences of
known classic HLA alleles, and 87,640 SNP variants
from the 1000 Genomes Project [28]. This approach
is considered to be an intermediate step between de
novo assembly and mapping to a single reference, but
requires careful attention to the variation included in
the PRG [27].
Despite the development of new tools to investigate
MHC variation, the robustness of imputation depends
largely on the reference panel and SNP selection. The
frequency of alleles can differ between populations, thus
highlighting the need to use population-specific refer-
ence panels to impute MHC alleles and amino acids.
Additionally, the use of many samples is possible for
analyzing the non-additive effects of MHC alleles on a
wide scale, as described by Lenz et al. for celiac disease
(CeD), psoriasis, and type 1 diabetes (T1D) [29]. These
non-additive effects could explain our inability to iden-
tify susceptibility variants. However, one important limi-
tation of existing imputation methods is that they are
limited to the classic MHC alleles and their amino acids.
Another limitation is that accuracy is lower for low fre-
quency or rare variants [20, 30]; this can be improved by
increasing the reference panel size, together with the use
of deep sequencing data. Ascertainment bias and lower
LD also make it challenging to impute MHC variants in
some non-European populations, such as Africans.
MHC genetic variation mediates susceptibility to a
wide range of complex diseases, including infectious and
autoimmune diseases. The large volume of data gener-
ated by recent GWAS has provided an excellent oppor-
tunity to apply imputation tools used to fine-map MHC
associations to classic alleles and amino acids, as de-
scribed below for autoimmune diseases. Overall, MHC
imputation has proved to be a robust and cost-effective
way to identify causal genes underlying disease patho-
genesis. Ultimately, knowing the causal genes will help
explain disease heritability and lead to a better under-
standing of the molecular pathways involved in disease
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Insights into MHC susceptibility for autoimmune diseases:
fine-mapping results, epistasis, and disease biology
Associations between the MHC and autoimmune dis-
eases reported in the 1970s were some of the earliest
described genetic associations [31, 32], and they remain
the strongest risk factors for autoimmune diseases. After
the development of wide-screen genotyping platforms
and imputation pipelines, MHC imputation and fine-
mapping were performed in European and Asian
populations for most common autoimmune diseases,
including RA [19, 25, 33, 34], CeD [35], psoriasis [36],
ankylosing spondylitis (AS) [37], systemic lupus erythe-
matosus (SLE) [33, 38–41], T1D [42, 43], multiple scler-
osis (MS) [44, 45], Graves’ disease [24], inflammatory
bowel disease (IBD) [46], and dermatomyositis (DM)
[47]. Table 1 shows the main associated variants and in-
dependently associated loci for autoimmune diseases.
In 2012, a pioneering MHC fine-mapping study, per-
formed in individuals of European ancestry with RA
[19], confirmed the strongest association with the class
II HLA-DRB1 gene, as well as other independent associ-
ations. Previously an increased risk of RA was reported
for a set of consensus amino acid sequences at positions
70–74 in the HLA-DRB1 gene, known as the “shared
epitope” locus [48]. The imputed data revealed the most
significant associations were with two amino acids at
position 11, located in a peptide-binding groove of the
HLA-DR heterodimer. This suggested a functional role
for this amino acid in binding the RA-triggering antigen.
Similar fine-mapping studies followed for other auto-
immune diseases (Table 1).
In general, in most autoimmune diseases, fine-
mapping strategies have confirmed the main associated
locus reported by serotype analysis within a certain
MHC locus. Such strategies have also allowed identifica-
tion of specific allelic variants or amino acids, as well as
independent variants in different HLA classes. For in-
stance, in CeD, the strongest association was with the
known DQ-DR locus, and five other independent signals
in classes I and II were also identified. CeD is the only
autoimmune disease for which the antigen, gluten, is
known and well studied. Gluten is a dietary product in
wheat, barley, and rye. It is digested in the intestine and
deamidated by tissue transglutaminase enzymes such
that it perfectly fits the binding pockets of a particular
CeD-risk DQ heterodimer (encoded by the DQ2.2,
DQ2.5, and DQ8 haplotypes). This association was con-
firmed by MHC fine-mapping, which indicated roles for
four amino acids in the DQ genes with the strongest in-
dependent associations to CeD risk [35]. Similarly, the
main associations were determined for T1D, MS, and
SLE within the MHC class II locus (the associations for
these three diseases are to a particular HLA-DQ-DRhaplotype), and there are also independent, but weaker
associations with the class I and/or III regions. In DM,
fine mapping in an Asian population identified MHC as-
sociations driven by variants located around the MHC
class II region, with HLA-DP1*17 being the most signifi-
cant [47]. In contrast, the primary and strongest associa-
tions in psoriasis and AS were to MHC class I
molecules, while independent associations to the class I
locus were also reported for IBD and Graves’ disease.
Class III variants are weakly implicated in autoimmune
diseases, but several associations in the MHC class III
region were seen for MS; for instance, the association to
rs2516489 belonging to the long haplotype between
MICB and LST1 genes. The association signal to
rs419788-T in the class III region gene SKIV2L has also
been implicated in SLE susceptibility, representing a
novel locus identified by fine-mapping in UK parent–
child trios [39]. An independent association signal to
class III was also identified (rs8192591) by a large meta-
analysis of European SLE cases and controls and, specif-
ically, upstream of NOTCH4 [40]. However, further
studies are needed to explain how these genetic varia-
tions contribute to predisposition to SLE.
In addition to identifying independent variants, MHC
fine-mapping studies permit analysis of epistatic and
non-additive effects in the locus. These phenomena
occur when the effect of one allele on disease manifest-
ation depends on the genotype of another allele in the
locus (non-additive effect), or on the genotype of the
“modifier” gene in another locus (epistasis). Non-
additive MHC effects were established in CeD, in which
knowing gluten was the causal antigen offered an advan-
tage in investigating the antigen-specific structure of the
DQ-heterodimer. CeD risk is mediated by the presence
of several HLA-DQ haplotypes, including the DQ2.5,
DQ2.2, and DQ8 haplotypes, which form the specific
pocket that efficiently presents gluten to T cells. These
haplotypes can be encoded either in cis, when both
DQA1 and DQB1 are located on the same chromosome,
or in trans, when they are located on different chromo-
somes. Some DQ allelic variants confer susceptibility to
CeD only in combination with certain other haplotypes,
forming a CeD-predisposing trans-combination. For ex-
ample, HLA-DQA1*0505-DQB1*0301 (DQ7) confers
risk to CeD only if it is combined with DQ2.2 or DQ2.5,
contributing to the formation of susceptible haplotypes
in trans. In particular, DQ7/DQ2.2 heterozygosity con-
fers a higher risk for CeD than homozygosity for either
of these alleles, and is an example of a non-additive
effect for both alleles.
Unlike CeD, the exact haplotypes and their associated
properties remain unknown for most other autoimmune
diseases; therefore, analyzing non-additive effects might
yield new insights into potentially disease-causing
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additive effects for autoimmune diseases, including CeD,
RA, T1D, and psoriasis, which were explained by interac-
tions between certain classic HLA alleles [29]. For in-
stance, specific interactions that increase T1D disease risk
were described between HLA-DRB1*03:01-DQB1*02:01/
DRB1*04:01-DQB1*03:02 genotypes [49] and for several
combinations of the common HLA-DRB1, HLA-
DQA1, and HLA-DQB1 haplotypes [43]. In AS, epi-
static interaction was observed for combinations of
HLA-B60 and HLA-B27, indicating that individuals
with the HLA-B27+/HLA-B60+ genotype have a high
risk of developing AS [50]. Moreover, a recent study
in MS found evidence for two interactions involving
class II alleles: HLA-DQA1*01:01-HLA-DRB1*15:01
and HLA-DQB1*03:01-HLA-DQB1*03:02, although
their contribution to the missing heritability in MS
was minor [44].
Epistatic interactions between MHC and non-MHC
alleles have also been reported in several autoimmune
diseases, including SLE, MS, AS, and psoriasis. For in-
stance, in a large European cohort of SLE patients, the
most significant epistatic interaction was identified
between the MHC region and cytotoxic T lymphocyte
antigen 4 (CTLA4) [9], which is upregulated in T cells
upon encountering APCs. This highlights that appropri-
ate antigen presentation and T-cell activation are im-
portant in SLE pathogenesis [9]. Notably, interactions
between MHC class I and specific killer immunoglobulin
receptor (KIR) genes are important in predisposition to
autoimmune diseases such as psoriatic arthritis, sclero-
derma, sarcoidosis, and T1D [51–54]. KIR genes are
encoded by the leukocyte receptor complex on chromo-
some 19q13 and expressed on natural killer cells and
subpopulations of T cells [55]. Finally, epistatic interac-
tions between MHC class I and ERAP1 have been
described for AS, psoriasis, and Behçet’s disease [10].
Association of novel MHC variants and identification
of interaction effects within the MHC are increasing our
understanding of the biology underlying autoimmune
and inflammatory diseases. Fine-mapping the main asso-
ciated locus within HLA-DQ-DR haplotypes has allowed
determination of the key amino acid positions in the DQ
or DR heterodimer. Pinpointing specific amino acids
leads to a better understanding of the structure and
nature of potential antigens for autoimmune or inflam-
matory diseases, and these can then be tested through
binding assays and molecular modeling. The fact that
these positions are located in peptide-binding grooves
suggests they have a functional impact on antigenic pep-
tide presentation to T cells, either during early thymic
development or during peripheral immune responses
[19]. In addition, analysis of non-additive effects in
MHC-associated loci offers the possibility to identifyantigen-specific binding pockets and key amino acid
sequences. For example, identification of the protective,
five-amino acid sequence DERAA as a key sequence in
the RA-protective HLA-DRB1:13 allele, and its similarity
to human and microbial peptides, led to identification of
(citrullinated) vinculin and some pathogen sequences as
novel RA antigens [56].
The identification of independent signals in MHC
classes I and III for many autoimmune diseases im-
plies that these diseases involve novel pathway mech-
anisms. For example, association of CeD to class I
molecules suggests a role for innate-like intraepithelial
leucocytes that are restricted to class I expression and
that are important in epithelial integrity and pathogen
recognition [57]. Class I associations to RA, T1D, and
other autoimmune diseases suggest that CD8+ cyto-
toxic cells are involved in disease pathogenesis, as
well as CD4+ helper T cells.
Discovering the epistatic effects of MHC and non-
MHC loci can also shed light on disease mechanisms.
For example, ERAP1 loss-of-function variants reduce
the risk of AS in individuals who are HLA-B27-
positive and HLAB-40:01-positive, but not in carriers
of other risk haplotypes [37]. Similar epistatic effects
were also observed for psoriasis, such that individuals
who carry variants in ERAP1 showed an increased
risk only when they also carried an HLA-C risk allele
[58]. In line with these observations, mouse studies
have shown that ERAP1 determines the cleavage of
related epitopes in such a way that they can be pre-
sented by the HLA-B27 molecule [37]. Confirming
that certain epitopes must be cleaved by ERAP1 to be
efficiently presented by CD4+ and CD8+ cells will be
a critical step in identifying specific triggers for auto-
immune diseases.
The recent discoveries of genetic associations be-
tween MHC alleles and autoimmune diseases are re-
markable and offer the potential to identify disease-
causing antigens. This would be a major step towards
developing new treatments and preventing disease.
However, we still do not understand exactly how
most associated alleles and haplotypes work, and ex-
tensive functional studies are needed to clarify their
involvement in disease.
Explained heritability by independent MHC loci for
autoimmune diseases
Heritability is an estimation of how much variation in a
disease or phenotype can be explained by genetic vari-
ants. Estimating heritability is important for predicting
diseases but, for common diseases, it is challenging and
depends on methodological preferences, disease preva-
lence, and gene–environment interactions that differ for
each phenotype [59]. It is therefore difficult to compare
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many diseases, estimates have been made as to how
much phenotypic variance can be explained by the main
locus and by independent MHC loci [29].
For autoimmune diseases with a main association
signal coming from a class II locus, the reported vari-
ance explained by MHC alleles varies from 2 − 30%
[9]. The strongest effect is reported for T1D, in which
the HLA-DR and HLA-DQ haplotypes explain 29.6%
of phenotypic variance; independently associated loci
in HLA-A, HLA-B, and HLA-DPB1 together explain
about 4% of the total phenotypic variance, while all
other non-MHC loci are responsible for 9% [60].
Similarly, in CeD, which has the same main associ-
ated haplotype as T1D, the HLA-DQ-DR locus ex-
plains 23 − 29% of disease variance (depending on the
estimated prevalence of disease, which is 1 − 3%),
whereas other MHC alleles explain 2 − 3%, and non-
MHC loci explain 6.5 − 9% [35]. In seropositive RA,
9.7% of phenotypic variance is explained by all the as-
sociated DR haplotypes, whereas a model including
three amino acid positions in DRB1, together with in-
dependently associated amino acids in HLA-B and
HLA-DP loci, explains 12.7% of the phenotypic vari-
ance [19]. This indicates that non-DR variants explain
a proportion of heritability comparable to that in
other non-MHC loci (4.7 − 5.5% in Asians and Euro-
peans) [19]. The non-additive effects of DQ-DR hap-
lotypes can also explain a substantial proportion of
phenotypic variance: 1.4% (RA), 4.0% (T1D), and 4.1%
(CeD) [29]. In MS, the major associated allele,
DRB1*15:01, accounts for 10% of the phenotypic vari-
ance, whereas all the alleles in DRB1 explain 11.6%.
A model including all of the independent variants
(and those located in classes I, II, and III) explains
14.2% of the total variance in MS susceptibility [45].
In SLE, the proportion of variance explained by the
MHC is notably lower, at only 2% [41], and is mostly
due to class II variants. In IBD, the association with
MHC is weaker than in classic autoimmune diseases,
with a lower contribution seen in Crohn’s disease (CD)
than in ulcerative colitis (UC) [61]. The main and sec-
ondary variants can now explain 3.1% of heritability in
CD and 6.2% in UC, which is two to ten times greater
than previously attributed by main effect analysis in ei-
ther disease (0.3% in CD and 2.3% in UC for the main
SNP effect) [46]. Among all the diseases discussed here,
the main effect of the associated haplotype is far stron-
ger than the independent effects from other loci (with
the exception of IBD, in which the MHC association is
weaker overall). However, independent MHC loci can
now explain a comparable amount of the disease vari-
ance to that explained by the non-MHC associated
genes known so far.Insights into MHC susceptibility for infectious diseases:
GWAS, fine-mapping results, and epistasis
In principle, an infectious disease is caused by inter-
actions between a pathogen, the environment, and
host genetics. Here, we discuss MHC genetic associa-
tions reported in infectious diseases from GWAS
(Table 2) and how these findings can explain in-
creased susceptibility or protection by affecting
human immune responses. This is why certain MHC
classes are important in infectious diseases. We note
that fewer MHC associations have been found for in-
fectious diseases than for autoimmune diseases,
mainly because of the smaller cohort sizes for infec-
tious diseases. Thus, extensive fine-mapping studies
(and imputation) have yet to be performed, with the
exception of a few studies on infections such as hu-
man immunodeficiency virus (HIV) [62], human
hepatitis B virus (HBV) [63, 64], human hepatitis C
virus (HCV) [65], human papilloma virus (HPV) sero-
positivity [66], and tuberculosis [67].
From a genetic viewpoint, one of the best-studied in-
fectious diseases is HIV infection. MHC class I loci have
strong effects on HIV control [62, 68–71] and acquisi-
tion [72], viral load set point [69–71], and non-
progression of disease [73] in Europeans [69, 70, 72, 73],
and in multi-ethnic populations (Europeans, African-
Americans, Hispanics, and Chinese) [62, 68, 71]. A
GWAS of an African-American population indicated a
similar HIV-1 mechanism in Europeans and African-
Americans: about 9.6% of the observed variation in viral
load set point can be explained by HLA-B*5701 in
Europeans [69], while about 10% can be explained by
HLA-B*5703 in African-Americans [68]. In contrast, the
MHC associations and imputed amino acids identified
in Europeans and African-Americans were not replicated
in Chinese populations, possibly because of the varied or
low minor allele frequencies of these SNPs in Chinese
people [71]. A strong association to the MHC class I
polypeptide-related sequence B (MICB) was also re-
vealed by a recent GWAS for dengue shock syndrome
(DSS) in Vietnamese children [74]. This result was repli-
cated in Thai patients, indicating MICB can be a strong
risk factor for DSS in Southeastern Asians [75].
HLA-DP and HLA-DQ loci, along with other MHC or
non-MHC loci (TCF19, EHMT2, HLA-C, HLA-DOA,
UBE2L3, CFB, CD40, and NOTCH4) are consistently as-
sociated with susceptibility to HBV infection in Asian
populations [76–83]. Significant associations between
the HLA-DPA1 locus and HBV clearance were also con-
firmed in independent East Asian populations [79, 81].
A fine-mapping study of existing GWAS data from Han
Chinese patients with chronic HBV infection used
SNP2HLA as the imputation tool and a pan-Asian refer-
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15, rs400488 at HCG9, and HLA-DRB1*13; together,
these four associations could explain over 72.94% of the
phenotypic variance caused by genetic variations [64].
Another recent study using imputed data from Japanese
individuals indicated that class II alleles were more
strongly associated with chronic HBV infection than
class I alleles (Additional file 1) [63]. Similarly, the HLA-
DQ locus influences the spontaneous clearance of HCV
infection in cohorts of European and African ancestry,
while DQB1*03:01, which was identified by HLA geno-
typing together with the non-MHC IL28B, can explain
15% of spontaneous HCV infection clearance cases [65].
HLA-DQB1*03 also confers susceptibility to chronic
HCV in Japanese people [84]. A GWAS in a European
population revealed that HPV8 seropositivity is influ-
enced by the MHC class II region [85]. However, HPV
type 8 showed a higher seropositivity prevalence than
other HPV types at the population level [66]; this led to
a limited power to detect associations with other HPV
types. Fine-mapping using the same European popula-
tion as in the GWAS [66] revealed significant associa-
tions with HPV8 and HPV77 seropositivity, but only
with MHC class II alleles, not with class I alleles. This
indicates a pivotal role for class II molecules in antibody
immune responses in HPV infection. Notably in this
study, imputation was performed using HLA*IMP:02
and reference panels from the HapMap Project [86] and
the 1958 British Birth Cohort, as well as using
SNP2HLA with another reference panel from the
T1DGC. Both imputation tools provided comparable re-
sults, thus highlighting the important role of MHC class
II alleles in antibody response to HPV infection [66].
A GWAS on leprosy in Chinese populations
pointed to significant associations with HLA-DR-DQ
loci [87, 88]; these results were replicated in an In-
dian population [89]. Fine-mapping the MHC showed
that variants in HLA class II were extensively associated
with susceptibility to leprosy in Chinese people, with
HLA-DRB1*15 being the most significant variant [87].
HLA class II variants also influence the mycobacterial in-
fection tuberculosis in European and African populations
[67, 90]. Fine-mapping identified the DQA1*03 haplotype,
which contains four missense variants and contributes to
disease susceptibility [67]. A meta-analysis showed that
five variants (HLA-DRB1*04, *09, *10, *15, and *16) in-
crease the risk of tuberculosis, especially in East Asian
populations, whereas HLA-DRB1*11 is protective [91].
Using a population from Brazil, the first GWAS on
visceral leishmaniasis revealed that the class II HLA-
DRB1-HLA-DQA1 locus had the strongest association
signal; this was replicated in an independent Indian
population [92]. This common association suggests that
Brazilians and Indians share determining genetic factorsthat are independent of the different parasite species in
these geographically distinct regions.
Finally, epistatic interactions between MHC class I
alleles and certain KIR alleles (between KIR3DS1 com-
bined with HLA-B alleles) are associated with slower
progression to acquired immunodeficiency syndrome
(AIDS) [93] and better resolution of HCV infection
(between KIR2DL3 and its human leukocyte antigen C
group 1, HLA-C1) [94].
Insights into the biology of infectious diseases
Associations with the MHC class I locus suggest a crit-
ical role for CD8+ T-cell responses in major viral infec-
tions such as HIV, dengue, and HCV. This critical role
of CD8+ T-cell responses in HIV infection is reflected by
the slow disease progression seen in infected individuals
because of their increasing CD8+ T-cell responses that
are specific to conserved HIV proteins such as Gap p24
[95]. Interestingly, five out of six amino acid residues
(Additional file 1) identified as associated with HIV con-
trol [62] lie in the MHC class I peptide-binding groove,
implying that MHC variation affects peptide presenta-
tion to CD8+ T cells. In particular, the amino acid at
position 97, which lies in the floor of the groove in
HLA-B, was most significantly associated with HIV con-
trol (P = 4 × 10−45) [62]. This amino acid is also impli-
cated in MHC protein folding and cell surface
expression [96]. An association found in severe dengue
disease also underscores the role of CD8+ T cells in dis-
ease pathogenesis: class I alleles that were associated
with an increased risk of severe dengue disease were also
associated with weaker CD8+ T-cell responses in a Sri
Lankan population from an area of hyper-endemic den-
gue disease [97]. In HCV, similar to the protective alleles
against HIV infection [95], HLA-B*27 presents the most
conserved epitopes of HCV to elicit strong cytotoxic T-
cell responses, thereby reducing the ability of HCV to
escape from host immune responses [98].
Associations between genetic variants in the MHC
class II region and disease susceptibility imply that im-
paired antigen presentation or unstable MHC class II
molecules contribute to insufficient CD4+ T-cell re-
sponses and, subsequently, to increased susceptibility to
infections. For instance, the amino acid changes at posi-
tions of HLA-DPβ1 and HLA-DRβ1 in the antigen-
binding groove that influence HBV infection may result
in defective antigen presentation to CD4+ T cells or to
impaired stability of MHC class II molecules, thereby
increasing susceptibility to HBV infection [64]. CD4+
T-cell responses are also critical in mycobacterial in-
fections, such as has been described for leprosy and
tuberculosis [99, 100]. Notably, monocyte-derived
macrophages treated with live Mycobacterium leprae
showed three main responses that explain infection
Matzaraki et al. Genome Biology  (2017) 18:76 Page 15 of 21persistence: downregulation of certain pro-inflammatory
cytokines and MHC class II molecules (HLA-DR and
HLA-DQ), preferentially primed regulatory T-cell re-
sponses, and reduced Th1-type and cytotoxic T-cell func-
tion [99]. Macrophages isolated from the lesions of
patients with the most severe disease form, lepromatous
leprosy, also showed lower expression of MHC class II
molecules, providing further evidence that defective
antigen presentation by these molecules leads to more
persistent and more severe M. leprae infection [99].
Recently, it has been shown that CD4+ T-cells are es-
sential for the optimal production of IFNγ by CD8+ T-
cells in the lungs of mice infected with M. tuberculosis,
indicating that communication between these two
distinct effector cell populations is critical for a protect-
ive immune response against this infection [101].
Impaired antigen processing and presentation from
Leishmania-infected macrophages (which are the pri-
mary resident cells for this parasite) to CD4+ T cells
could explain increased susceptibility to leishmaniasis
[102]. The association between HPV seropositivity and
the MHC class II region also suggests that class II mole-
cules bind and present exogenous antigens more effect-
ively to a subset of CD4+ T cells known as Th2. These
Th2 cells help primed B lymphocytes to differentiate
into plasma cells and to secrete antibodies against the
HPV virus.
In support of the hypothesis that genetic effects on both
CD8+ (class I) and CD4+ (class II) cells modify the predis-
position to infections, it should be noted that some infec-
tious diseases, such as HIV, HBV, HCV, and leprosy, show
associations to more than one of the classic MHC classes
and, in some cases, the associations differ between popu-
lations (Table 2). Moreover, consideration must be given
to the differences between viral and bacterial genotypes in
the same infection, which play a role in determining
potentially protective effects. Overall, associations with
multiple MHC loci reflect the complex and interactive
nature of host immune responses when the host encoun-
ters a pathogen.
Relationship between the MHC variants involved
in autoimmune and infectious diseases
Both autoimmune and infectious diseases seem to in-
volve certain MHC classes (Fig. 2a), and only a few
MHC alleles are shared between these two distinct dis-
ease groups (Fig. 2b). The identification of shared MHC
variation has provided insight into the relationships be-
tween the MHC variants involved in autoimmune and
infectious diseases and which have been uniquely shaped
throughout human evolution [18].
Two hypotheses have been proposed to explain the re-
lationships between the MHC variants involved in both
groups of diseases. The first, known as the “pathogen-driven selection” hypothesis, states that pressure exerted
on the human genome by pathogens has led to the
advantageous selection of host defense genes and, subse-
quently, to much higher polymorphism in the MHC.
This polymorphism has contributed to the development
of complex immune defense mechanisms that protect
humans against a broad range of pathogens. Thus, het-
erozygosity at MHC loci is evolutionarily favored and
has become an efficient mechanism contributing to the
highly polymorphic MHC (the “MHC heterozygosity
advantage”) [103]. Two examples of MHC heterozygote
advantage are HIV-1-infected heterozygotes at class I
loci, which are slower to progress to AIDS [104, 105],
and HBV-infected heterozygotes at class II loci, which
seem more likely to clear the infection [106]. In addition,
human populations exposed to a more diverse range of
pathogens display higher class I genetic diversity than
those exposed to a smaller range [107]. However, the
true effect of infectious diseases on selection might be
underestimated because of the heterogeneity of many
pathogens and the changing prevalence of infectious dis-
eases over evolutionary time.
Positive selection of the advantageous effect of MHC
polymorphism in infections may also be accompanied by
a higher risk of developing autoimmune diseases. For
example, the non-MHC locus SH2B3 rs3184504*A is a
risk allele for CeD but has been under positive selection
because it offers the human host protection against bac-
terial infections [108]. To investigate whether other gen-
etic variants in the MHC show this opposite direction
effect between autoimmune and infectious diseases
(Fig. 2b), we compared SNPs and alleles in the MHC
identified by GWAS and fine-mapping studies on auto-
immune diseases (Table 1; Additional file 2) with those
identified in infectious diseases (Table 2; Additional file 1).
On the one hand, HLA-B*27:05, which has one of the
strongest associations to AS in the MHC (P < 1 × 10−2000)
[37] and is present in all ethnic groups, increases AS risk.
On the other hand, it also has a protective effect against
HIV infection, showing a nominal significant value of
5.2 × 10–5 [70]. The second example of opposite allelic ef-
fect is the association between the rs2395029*G allele and
susceptibility to psoriasis (OR = 4.1; P = 2.13 × 10–26) [109]
and AIDS non-progression (P = 9.36 × 10–12) [69]. Located
in the HLA complex P5 (HCP5), rs2395029 is a proxy for
the HLA-B*57:01 allele [69], the strongest protective allele
against AIDS progression [110]. Non-progressors carrying
the rs2395029-G allele had a lower viral load than other
non-progressors [73].
Another study showed that psoriasis patients carry the
same genetic variants as HIV controllers/non-progres-
sors and that they are particularly enriched for the
protective allele HLA-B*57:01 (P = 5.50 × 10–42) [111].
Moreover, the intergenic variant rs10484554*A, which is
a b
Fig. 2 Major histocompatibility complex allele associations with autoimmune and infectious diseases. a Abbreviations marked with an asterisk
indicate the autoimmune disease showing the strongest association with the specific locus. b Single nucleotide polymorphisms (SNPs) and
alleles in the major histocompatibility complex (MHC) shared between autoimmune and infectious diseases. The blue area shows MHC alleles
located in the class I region and the green area shows those in the class II region. The blue arrows indicate either a protective effect of the genetic
variants against the infectious disease or a slower progression to the infectious disease. The red arrows indicate increased susceptibility to the
corresponding autoimmune or infectious disease. AIDS acquired immunodeficiency syndrome, AS ankylosing spondylitis, CD Crohn’s disease, CeD
celiac disease, DM dermatomyositis, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus, MS multiple sclerosis, Ps psoriasis,
RA rheumatoid arthritis, SLE systemic lupus erythematosus, T1D type 1 diabetes, TB tuberculosis, UC ulcerative colitis, HPV human papilloma virus
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with AIDS non-progression (P = 6.27 × 10–8) [73] and
with susceptibility to psoriasis (OR = 4.66, P = 4 × 10–214)
[58]. HLA-C*06:02 (equivalent to HLA-Cw6) was most
strongly associated with susceptibility to psoriasis (OR =
3.26; P = 2.1 × 10–201) [36] and is also protective against
HIV infection (OR = 2.97; P = 2.1 × 10 –19) [62]. The
same allele has been associated with susceptibility to CD
(OR = 1.17; P = 2 × 10–13) [46]. Interestingly, the role of
MHC in HIV control also relates to the influence of
MHC expression levels. For instance, rs9264942 shows
one of the most significant genome-wide effects ob-
served on HIV control [62, 69, 70]: it is located 35 kb
upstream of the HLA-C locus (Table 2) and has been as-
sociated with high HLA-C expression, conferring protec-
tion against HIV infection [112]. Explaining this
protective effect, HLA-C allelic expression was corre-
lated with increasing likelihood of CD8+ T-cell cytotox-
icity [112]. However, the −35 SNP is not a causal variant,
but is in LD with a SNP at the 3′ end of HLA-C; this af-
fects HLA-C expression by influencing binding of the
microRNA Hsa-miR-148a [113]. Notably, high HLA-C
expression has a deleterious effect by conferring risk for
Crohn’s disease [113]. The potential mechanism bywhich HLA expression levels confer resistance to
pathogens, and also lead to greater autoimmunity,
could be through promiscuous peptide binding [114].
Lastly, HLA-DQB1*03:02 showed a dominant risk
effect for MS (OR = 1.30; P = 1.8 × 10–22) [45], whereas
it is a resistant allele against chronic HBV infection
(OR = 0.59; P = 1.42 × 10–5) [63].
The second hypothesis states that pathogens can
trigger autoimmunity, as suggested by epidemiological
studies [115, 116]. For example, it has recently been
shown that apoptosis of infected colonic epithelial cells
in mice induces the proliferation of self-reactive CD4+ T
cells that are specific to cellular and to pathogenic anti-
gens [117]. Self-reactive CD4+ T cells differentiate into
Th17 cells, which promote production of auto-antibodies
and auto-inflammation, implying that infections can trig-
ger autoimmunity [117]. Other mechanisms have been
proposed, such as molecular mimicry, bystander activa-
tion, exposure of cryptic antigens, and superantigens
[118]. Common genetic signatures between autoimmune
and infectious diseases indirectly imply that pathogens
can indeed trigger autoimmunity. In line with this second
hypothesis, we have identified common risk factors
between autoimmune and infectious diseases, such as the
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(OR = 2.11; P = 3.5 × 10–28) [87]; rs9275572*C, located in
HLA-DQ, for chronic HCV infection (OR = 0.71; P =
2.62 × 10–6) [84], and SLE (P = 1.94 × 10–6) [119]; HLA-
DQB1*03:02 for MS (OR = 1.30; P = 1.8 × 10–22) [45] and
pulmonary tuberculosis (OR = 0.59; P = 2.48 × 10–5) [67];
HLA-C*12:02 for UC (OR = 2.25; P = 4 × 10–37) [46], CD
(OR = 1.44; P = 3x 10–8) [46], and chronic HBV infection
(OR = 1.70; P = 7.79 × 10–12) [63]; and rs378352*T, located
in HLA-DOA, for chronic HBV infection (OR = 1.32; P =
1.16 × 10–7) [78] and RA (OR = 1.24; P = 4.6 × 10–6) [25]
(Fig. 2a).
Associations within the MHC region for several auto-
immune diseases, such as RA, CeD, AS, T1D, Graves’ dis-
ease, and DM, and HBV infection are driven by variants
and alleles around HLA-DPB1 (Table 1), implying that
viruses like HBV could trigger autoimmunity. Although
there is no convincing evidence, HBV and HCV are associ-
ated with extra-hepatic autoimmune perturbations [120,
121]. Lastly, the DQA1*03:01 allele, which contributes to
tuberculosis susceptibility (OR = 1.31; P = 3.1 × 10–8) [67],
is also a well-known risk factor for CeD as part of the DQ8
(DQA1*03-DQB1*03:02) and DQ2.3 (trans-DQA1*03:01
and DQB1*02:01) haplotypes [122]. DQA1*03 also in-
creases susceptibility to T1D, RA, and juvenile myositis
[123–125]. Overall, the direction of association is the same
for most shared MHC class II loci, suggesting that bacteria
and viruses can trigger immune responses. No viruses have
been proven to cause an autoimmune disease thus
far, but multiple virus infections could prime the im-
mune system and eventually trigger an autoimmune
response; this is a hypothesis that has been supported
by animal studies on MS [126].
Conclusions and future perspectives
We have discussed recent advances in understanding the
genetic variation in the MHC in relation to autoimmune
and infectious diseases. However, confidence in the associ-
ations between MHC and infectious diseases is limited,
mainly because of the relatively small patient cohort sizes
available. Further limitations to identifying and replicating
associations with infectious diseases include: strain differ-
ences, heterogeneity in clinical phenotypes, use of in-
appropriate controls (such as individuals with
asymptomatic infections), and population-specific differ-
ences in allele frequency and/or haplotype structure.
Finally, with the exception of a few described above, no
imputation has been performed in most infectious disease
studies. In certain populations, such as Africans, lower LD
makes it challenging to perform MHC imputation.
Although application of a traditional GWAS is chal-
lenging for infectious diseases, other approaches may
increase the power of genetic studies. For instance, a
combination of transcriptional analysis and systemsbiology allowed the identification of a novel role for type
I IFN signaling pathway in the human host immune
response against Candida albicans [127]. The use of
control subjects for whom it is known whether they
clear the infection, and who come from the same hos-
pital as patients, could be appropriate for infectious dis-
eases so that co-morbidities and clinical risk factors are
as similar as possible between groups. Overall, initiating
collaborative efforts to increase patient cohort numbers,
designing better studies by using more appropriate con-
trols and more homogenously clinically defined patient
phenotypes, and applying imputation using population-
specific reference genomes would open new avenues to
study the genetics of infectious diseases.
In contrast to infectious diseases, the added value of
fine-mapping the MHC to pinpoint genetic risk factors
for autoimmune disease has been well demonstrated by
numerous studies. The associations that have been
found in both European and Asian populations to the
same amino acids by fine-mapping the MHC suggest
that the same molecular mechanism is involved, despite
the differences in MHC allele frequencies seen between
these ethnic groups.
MHC-based imputation approaches using genotype
data, along with the use of population-specific reference
panels for imputing MHC alleles and amino acids, has
allowed identification of the MHC variation associated
with complex diseases. Although identification is chal-
lenging, genetic variation in the MHC is of critical im-
portance for two reasons. First, it sheds light on the
development of autoimmunity, given the two hypotheses
discussed above (pathogen-driven evolutionary selection
of protective genes or pathogens as triggers of auto-
immunity), and second, it yields greater understanding
of the complexity of the human immune system. This
knowledge will ultimately permit the design of better
prophylactic and therapeutic strategies to achieve more
balanced patient–immune responses during treatment.
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